Sonnenblick M, Rosin A
Department of Geriatrics, Shaare Zedek Medical Center, Jerusalem, Israel.
Chest. 1991 Mar;99(3):557-61. doi: 10.1378/chest.99.3.557.
Cardiovascular complications have occurred in clinical trials of interferon. We review herein experience to date of cardiotoxicity with all types of interferons in cancer patients. The most common presentations of cardiotoxicity were cardiac arrhythmia, dilated cardiomyopathy, and symptoms of ischemic heart disease, including myocardial infarction and sudden death. The cardiac effects were not related to the daily dose, cumulative total dose, or period of therapy. Some of the patients in whom interferon has caused cardiovascular sequelae have had a history of coronary heart disease or have previously been given chemotherapy with drugs known to be cardiotoxic. In most of the patients, cardiac toxicity was reversible following the cessation of the drug therapy.
心血管并发症曾出现在干扰素的临床试验中。我们在此回顾了迄今为止各类干扰素在癌症患者中引起心脏毒性的经验。心脏毒性最常见的表现为心律失常、扩张型心肌病以及缺血性心脏病症状，包括心肌梗死和猝死。心脏影响与每日剂量、累积总剂量或治疗时长无关。一些因干扰素出现心血管后遗症的患者有冠心病史，或此前曾接受过已知具有心脏毒性的药物化疗。在大多数患者中，药物治疗停止后心脏毒性是可逆的。
